VCYT Stock - Veracyte, Inc.
Unlock GoAI Insights for VCYT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $445.76M | $361.05M | $296.54M | $219.51M | $117.48M |
| Gross Profit | $298.14M | $248.15M | $194.95M | $145.11M | $76.03M |
| Gross Margin | 66.9% | 68.7% | 65.7% | 66.1% | 64.7% |
| Operating Income | $16.14M | $-85,795,000 | $-41,081,000 | $-81,903,000 | $-35,389,000 |
| Net Income | $24.14M | $-74,404,000 | $-36,560,000 | $-75,563,000 | $-34,909,000 |
| Net Margin | 5.4% | -20.6% | -12.3% | -34.4% | -29.7% |
| EPS | $0.32 | $-1.02 | $-0.51 | $-1.11 | $-0.66 |
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Visit WebsiteEarnings History & Surprises
VCYTEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 23, 2026 | $0.40 | — | — | — |
Q4 2025 | Nov 4, 2025 | $0.32 | $0.51 | +59.4% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $0.31 | $0.44 | +41.9% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $0.20 | $0.31 | +55.0% | ✓ BEAT |
Q1 2025 | Feb 24, 2025 | $0.10 | $0.36 | +260.0% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $0.03 | $0.19 | +603.7% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $0.05 | $0.30 | +530.8% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $-0.19 | $-0.02 | +89.5% | ✓ BEAT |
Q1 2024 | Feb 22, 2024 | $-0.07 | $-0.04 | +42.9% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-0.16 | $-0.03 | +81.3% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.16 | $-0.12 | +25.0% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $-0.14 | $-0.11 | +21.4% | ✓ BEAT |
Q1 2023 | Feb 22, 2023 | $-0.15 | $-0.05 | +66.7% | ✓ BEAT |
Q4 2022 | Nov 2, 2022 | $-0.24 | $-0.12 | +50.0% | ✓ BEAT |
Q3 2022 | Aug 2, 2022 | $-0.21 | $-0.13 | +38.1% | ✓ BEAT |
Q2 2022 | May 3, 2022 | $-0.23 | $-0.20 | +13.0% | ✓ BEAT |
Q1 2022 | Feb 28, 2022 | $-0.14 | $-0.15 | -7.1% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-0.14 | $-0.13 | +7.1% | ✓ BEAT |
Q3 2021 | Jul 29, 2021 | $-0.25 | $-0.13 | +48.0% | ✓ BEAT |
Latest News
Frequently Asked Questions about VCYT
What is VCYT's current stock price?
What is the analyst price target for VCYT?
What sector is Veracyte, Inc. in?
What is VCYT's market cap?
Does VCYT pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to VCYT for comparison